Lipase Inhibitor

(3Z,5E,11E)-3,5,11-Tri-decatriene-7,9-diyne-1,2-diacetate is a human pancreatic lipase inhibitor, with an IC₅₀ of 77.97 μM against human pancreatic lipase. (3Z,5E,11E)-3,5,11-Tri-decatriene-7,9-diyne-1,2-diacetate is applicable to the research of obesity.

Platycodin V is a triterpenoid saponin. Platycodin V has a relatively weak inhibitory effect on pancreatic lipase.

3'-O-Methylisosaponarin is a spsoscoparin glycoside found in the leaves of C. sativus cultivar Chinese Yellow. 3'-O-Methylisosaponarin shows weak anti-lipase activity. 3'-O-Methylisosaponarin can be used for the research of disturbances of lipid metabolism.

Ginsenoside F2 (Standard) is the analytical standard of Ginsenoside F2. This product is intended for research and analytical applications. Ginsenoside F2, a metabolite from Ginsenoside Rb1, induces apoptosis accompanied by protective autophagy in breast cancer stem cells.

Ro 20-0083 is an orally active pancreatic lipase inhibitor. Ro 20-0083 inhibits hPancreatic lipase activity, reduces lipid absorption and de novo fatty acid synthesis. Ro 20-0083 decreases food intake in Zucker rats. Ro 20-0083 can be used in obesity-related research.

MEDI-5884 (REG-101) is a humanized IgG4Pκ neutralizing monoclonal antibody targeting endothelial lipase (EL), with an IC₅₀ of 1.3 nM and 1.7 nM against human and cynomolgus monkey EL, respectively; its K_d values for human and cynomolgus monkey EL are 4.1 nM and 1.6 nM, respectively. MEDI-5884 increases plasma levels of HDL-C, apolipoprotein A1 (ApoA1) and phospholipids, while causing a slight increase in LDL-C and apolipoprotein B (ApoB) levels. MEDI-5884 can be used in research related to cardiovascular diseases, coronary heart disease, coronary atherosclerosis and stable coronary artery disease.

4,6,12-Tetradecatriene8,10-diyne-1,3-diacetate is a polyacetylene compound found in the rhizomes of Atractylodes lancea. 4,6,12-Tetradecatriene8,10-diyne-1,3-diacetate inhibits human pancreatic lipase, with an IC₅₀ of 55.67 μM and 16.7 μg/mL. 4,6,12-Tetradecatriene8,10-diyne-1,3-diacetate can block the digestion of triglycerides by inhibiting the activity of human pancreatic lipase. 4,6,12-Tetradecatriene8,10-diyne-1,3-diacetate can be used in research on obesity.

Mogroside IV (Standard) is the analytical standard of Mogroside IV (HY-N6945). This product is intended for research and analytical applications. Mogroside IV is a pancreatic lipase inhibitor with a IC₅₀ of 289.09 µg/mL. Mogroside IV inhibits pancreatic lipase in a dose-dependent manner. Mogroside IV can be used in research related to obesity.

Isochiisanoside is a lupane-type triterpenoid triglycoside found in the leaves of Acanthopanax sessiliflorus. Isochiisanoside dose-dependently inhibits LPS (HY-D1056A1))-induced NO (IC₅₀ = 64.25 μM) and PGE₂ production in macrophages without obvious cytotoxicity. Isochiisanoside shows weak inhibitory activity against porcine pancreatic lipase. Isochiisanoside can be used in inflammation-related research.

α-Glucosidase-IN-122 is an inhibitor of α-glucosidase (α-Glucosidase). α-Glucosidase-IN-122 regulates glucose and lipid metabolism through multiple pathways, including inhibition of α-glucosidase and lipase, and exertion of antioxidant activity, and enhances glucose consumption in insulin-resistant HepG2 cells. α-Glucosidase-IN-122 can be used in the research of type 2 diabetes.

Ciwujianoside C1 is a saponin, that can be isolated from the leaves of Acanthopanax senticosus. Ciwujianoside C1 inhibits pancreatic lipase activity in vitro.

Salacinol, compound found in Salacia reticulata, is an orally active α-glucosidase/lipase inhibitor. Salacinol inhibits enzymatic activity of intestinal maltase (IC₅₀ = 3.2 μg/mL, K_i = 0.31 μg/mL), sucrase (IC₅₀ = 0.84 μg/mL, K_i = 0.32 μg/mL), and isomaltase (IC₅₀ = 0.59 μg/mL, K_i = 0.47 μg/mL), and inhibits increases in serum glucose levels in sucrose-loaded rats. Salacinol also inhibits pancreatic lipase and lipoprotein lipase. Salacinol can be used for the research of diabetes mellitus.

SMP-028 is an inhibitor of neutral cholesterol esterase (CEase), with an IC₅₀ of 1.01 μM.

Esterastin is a lipase inhibitor with an IC₅₀ value of 2 ng/mL when p-nitrophenyl acetate is used as a substrate.

GSK264220A (Standard) is the analytical standard of GSK264220A (HY-103372). This product is intended for research and analytical applications. GSK264220A is a potent endothelial lipase inhibitor with IC₅₀ of 16 nM. GSK264220A has the potential to decrease the risk of cardiovascular disease.

1-Isomangostin is an inhibitor of pancreatic lipase. 1-Isomangostin inhibits porcine pancreatic lipase with an IC₅₀ of 34.5 μM. 1-Isomangostin has anti-obesity activity.

KT195 is a serine hydrolase inhibitor that targets ABHD6 (IC₅₀ = 10 nM) and ABHD2, with no significant activity against DAGLβ. KT195 inhibits endoplasmic reticulum calcium release and mitochondrial calcium uptake by targeting ABHD2, thereby blocking A23187 (HY-N6687) and H₂O₂-induced necrotic cell death and apoptosis. By inhibiting ABHD6 activity, KT195 significantly induces 2-AG accumulation in Neuro2A cells and reduces IL-1β secretion in lipopolysaccharide-treated macrophages. KT195 has been used as a negative control probe for DAGLβ and can be applied in studies of ABHD6 and ABHD2 in calcium signaling, lipid metabolism, neuronal function, and inflammatory.

Sclerodione is a metabolite that can be produced by the Scleroderris canker fungus, Gremmeniellaabietina. Sclerodione has antifungal activity. Sclerodione is a lipase inhibitor (IC₅₀: 1 μM).

BemPPOX is an orally active, potent dog gastric lipase (DGL) inhibitor with X_l50 (the inhibitor molar excess leading to 50% lipase inhibition) of 0.5. BemPPOX is also a good inhibitor of GPLRP2 (x_l50=0.64). BemPPOX efficiently regulates the gastrointestinal lipolysis and slows down the overall lipolysis process in rats. BemPPOX has the potential for obesity research.

Fucoxanthinol, a carotenoid, is a deacetylated Fucoxanthin (HY-N2302) metabolite with oral activity, and inhibits rat pancreatic lipase with an IC₅₀ of 764 nM. Fucoxanthinol reduces expression of Bcl-2, Bcl-xL, survivin, XIAP, cIAP2, cyclin D1, cyclin D2, cyclin E, CDK4, CDK6, β-catenin, JunD, PPARγ, and induces GADD45α expression. Fucoxanthinol activates caspase-3, caspase-8, caspase-9, Nrf2/Keap1/ARE pathway, and inhibits activation of Akt, NF-κB, AP-1, PDPK1, GSK3β phosphorylation. Fucoxanthinol induces apoptosis, G0/G1 cell cycle arrest, inhibits cancer cell viability, proliferation, migration, invasiveness, tumour growth, adipocyte differentiation, oxidative stress, neurotoxicity, triglyceride absorption, angiogenesis, and obesity-induced inflammation. Fucoxanthinol can be used for the research of osteosarcoma, leukemia, lymphoma, adult T-cell leukemia, prostate cancer, colon cancer, breast cancer, hypertriglyceridaemia, Alzheimer’s disease, Parkinson’s disease, obesity, insulin resistance, malignant melanoma, and type II diabetes.